|
Adenocarcinoma of prostate
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Due to the similarities between human CaP tumors and the PSP-KIMAP tumors, this preclinical model may supplement the current transgenic models to study CaP more accurately.
|
15727931 |
2005 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
These data provide evidence for extremely rare apoptotic neuronal death in AD and PSP compatible with the progression of neuronal degeneration in these chronic diseases.
|
11205141 |
2000 |
|
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD.
|
15641585 |
2004 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Neurogranin was decreased in PD, PD with dementia, MSA, and PSP compared to controls and Alzheimer's disease.
|
31837067 |
2020 |
|
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
<b>Objectives:</b> The present study is geared to learning about the patterns of tau seeding and cells involved following unilateral inoculation in the corpus callosum of homogenates from sporadic Alzheimer's disease (AD), primary age-related tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic Pick bodies in neurons and tau containing fibrillar astrocytes), and frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 4Rtau familial tauopathy).
|
31191295 |
2019 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
N-224 tau concentrations in PSP and CBS were significantly lower than in AD (p < 0.0001) and did not correlate to t-tau and p-tau.
|
30547227 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The prognostic value of the pSP genes was validated in a large independent series of PDAC patients (n = 78) using nCounter analysis of expression (in tumor versus surrounding pancreatic tissue) and Cox regression for disease-free and overall survival.
|
24069258 |
2013 |
|
Anxiety
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, acute PSP intensity and frequency determined membership of women in PT3 (OR = 1.211, P = 0.033; OR = 3.000, P = 0.029, respectively), and postsurgical anxiety (OR = 1.182, P = 0.026) also played a key predictive role.
|
29419656 |
2018 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, acute PSP intensity and frequency determined membership of women in PT3 (OR = 1.211, P = 0.033; OR = 3.000, P = 0.029, respectively), and postsurgical anxiety (OR = 1.182, P = 0.026) also played a key predictive role.
|
29419656 |
2018 |
|
Argyrophilic grain disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
|
Atrophic acne scar
|
0.010 |
Biomarker
|
disease |
BEFREE |
PSP technique was found to be a safe and cost-effective treatment option for atrophic acne scars.
|
31414709 |
2019 |
|
Attention Deficit Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent.
|
10532621 |
1999 |
|
Attention deficit hyperactivity disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent.
|
10532621 |
1999 |
|
Atypical Parkinsonism
|
0.010 |
Biomarker
|
disease |
BEFREE |
We suggest possible aetiologies for this constellation of symptoms, discuss the possible origin of these signs and highlight this phenotype as it may mimic atypical parkinsonism and in particular PSP.
|
29801913 |
2018 |
|
Autoimmune Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33).
|
30161055 |
2018 |
|
Autonomic nervous system disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Subsequently, the diagnosis was changed to PSP due to hypometric downward gaze, reduced blink frequency, symmetric bradykinesia, rigidity, and the absence of autonomic dysfunction.
|
31216016 |
2019 |
|
Bipolar Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study investigated the validity of SRG-PSP in patients with bipolar disorder (BD).
|
28343053 |
2017 |
|
Bradykinesia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Subsequently, the diagnosis was changed to PSP due to hypometric downward gaze, reduced blink frequency, symmetric bradykinesia, rigidity, and the absence of autonomic dysfunction.
|
31216016 |
2019 |
|
Bradykinesia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism.
|
14502653 |
2003 |
|
Chronic calcifying pancreatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was concluded that PSP-S gene expression is specifically reduced in CCP patients.
|
2525567 |
1989 |
|
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
|
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
We enrolled 34 de novo PD patients and 29 patients affected by atypical parkinsonisms (Multiple System Atrophy, MSA, n = 10; Progressive Supranuclear Palsy, PSP, n = 12 and Corticobasal Degeneration, CBD, n = 7) who underwent an acute levodopa challenge.
|
28207803 |
2017 |
|
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |
|
Dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism.
|
14502653 |
2003 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Patients with BD were recruited from psychiatric outpatient clinics, and assessed with the Young Mania Rating Scale (YMRS), the Montgomery-Åsberg Depression Rating Scale (MADRS), the Clinical Global Impression Scale (CGI)-Bipolar and CGI-Depression, the Positive and Negative Symptom Scale (PANSS), the Global assessment of function (GAF), and the PSP.
|
28343053 |
2017 |